Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 29 Sep 2017 Status changed from suspended to active, no longer recruiting.
- 18 Jul 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated